Compassionate Use or Expanded Access of Dupilumab
← catalyst calendarSponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
—
Status
Available
Study type
Expanded access
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-09-01
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | — | When the study began enrolling | |
| Primary completion | — | The date the last participant is measured for the primary outcome — the readout window | |
| Study completion | — | The whole study's end, after follow-up | |
| First posted | 2021-03-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-09-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 2 Inflammatory Disorders
Intervention
- Drug: Dupilumab — also filed as REGN668, DUPIXENT®, SAR231893
Related
REGN · their whole pipeline · Who in Congress owns REGN? · Executive-branch trades in REGN
REGN's other studiesmost recently updated first
- A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation Phase 2 · Active, not recruiting
- Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy Phase 3 · Terminated
- A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread Phase 1 · Recruiting
- A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy Phase 3 · Recruiting
- A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Phase 2 · Recruiting
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed